This phase I study was designed to determine the maximum tolerated dose (MTD) and dose-limiting side effects of combination treatment with paclitaxel (Taxol) and UFT (uracil and tegafur in a 4:1 molar ratio) plus oral
Steven Benner, MD
Advertisement
Articles by Steven Benner, MD
Advertisement
Latest Updated Articles
- Paclitaxel and UFT Plus Oral Calcium Folinate in Pretreated Metastatic Breast Cancer
Published: July 1st 1999 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Trastuzumab Deruxtecan Regimen Accepted for Review in HER2+ Breast Cancer
2
FDA Approves Lurbinectedin/Atezolizumab Maintenance in ES-SCLC
3
FDA Grants Fast Track Designation to Novel PIK3α Inhibitor in Breast Cancer
4
Uncovering Subsequent Research Considerations for Tarlatamab in ES-SCLC
5
